Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

h.j. harkins company, inc. - halobetasol propionate (unii: 91a0k1ty3z) (halobetasol - unii:9p6159hm7t) - halobetasol propionate 0.5 mg in 1 g - halobetasol propionate ointment, 0.05% is a super-high potency corticosteroid indictated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond two consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. halobetasol propionate ointment, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

physicians total care, inc. - halobetasol propionate (unii: 91a0k1ty3z) (halobetasol - unii:9p6159hm7t) - halobetasol propionate 0.5 mg in 1 g - halobetasol propionate ointment, 0.05% is a super-high potency corticosteroid indictated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond two consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. halobetasol propionate ointment, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

physicians total care, inc. - halobetasol propionate (unii: 91a0k1ty3z) (halobetasol - unii:9p6159hm7t) - halobetasol propionate 0.5 mg in 1 g - halobetasol propionate cream, 0.05% is a super-high potency corticosteroid indictated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond two consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. use in children under 12 years of age is not recommended. as with other highly active corticosteroid, therapy should be discontinued when control has been achieved. if no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. halobetasol propionate cream, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

sola pharmaceuticals - halobetasol propionate (unii: 91a0k1ty3z) (halobetasol - unii:9p6159hm7t) - halobetasol propionate ointment is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

cosette pharmaceuticals, inc. - halobetasol propionate (unii: 91a0k1ty3z) (halobetasol - unii:9p6159hm7t) - halobetasol propionate ointment 0.05% is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond two consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. use in children under 12 years of age is not recommended. as with other highly active corticosteroids, therapy should be discontinued when control has been achieved. if no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. halobetasol propionate ointment is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

quagen pharmaceuticals llc - halobetasol propionate (unii: 91a0k1ty3z) (halobetasol - unii:9p6159hm7t) - halobetasol propionate ointment 0.05% is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond two consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. use in children under 12 years of age is not recommended. as with other highly active corticosteroids, therapy should be discontinued when control has been achieved. if no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. halobetasol propionate ointment is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

bryant ranch prepack - halobetasol propionate (unii: 91a0k1ty3z) (halobetasol - unii:9p6159hm7t) - halobetasol propionate ointment, 0.05% is a super-high potency corticosteroid indictated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond two consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. halobetasol propionate ointment, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

bryant ranch prepack - halobetasol propionate (unii: 91a0k1ty3z) (halobetasol - unii:9p6159hm7t) - halobetasol propionate ointment, 0.05% is a super-high potency corticosteroid indictated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond two consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. halobetasol propionate ointment, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

bryant ranch prepack - halobetasol propionate (unii: 91a0k1ty3z) (halobetasol - unii:9p6159hm7t) - halobetasol propionate cream, 0.05% is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond two consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. use in children under 12 years of age is not recommended. as with other highly active corticosteroids, therapy should be discontinued when control has been achieved. if no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. halobetasol propionate cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

mayne pharma - halobetasol propionate (unii: 91a0k1ty3z) (halobetasol - unii:9p6159hm7t) - halobetasol propionate topical foam is indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. none. risk summary there are no available data on halobetasol propionate topical foam use in pregnant women to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. published data report an increased risk of low birthweight with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. in animal reproduction studies, increased malformations, including cleft palate and omphalocele, were observed after oral administration of halobetasol propionate during organogenesis to pregnant rats and rabbits. no comparisons of animal exposure with human exposure may be calculated due to minimal systemic exposure in humans after topical administration of halobetasol propionate topical foam [see clinical pharmacology (12.3) ]. the background risk of major birth defects and miscarriage for the indica